Molecular engineering for health

Trimerbody : The next generation of therapeutic antibodies
LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most prevalent on the market. 
 
Our drug candidates are derived from in-house R&D and our collaborations with reference research centers and other companies. We have several proprietary programs developing in multiple therapeutic areas, including immune-oncology, which is a high-growth area for companies and investors. LeadArtis offers an opportunity to participate in the development of cutting-edge immunomodulatory therapies against cancer.
Trimerbody® is a registered trademark and is covered by international patents.

OUR VISION

By creating new medicines, we can create hope for future patients suffering from cancers for which current therapies are inadequate.

Next Generation of Therapeutic Antibodies

Understanding Trimerbodies

Trimerbody is a novel class of proprietary multivalent and multispecific therapeutic proteins

Our company

LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies

Strategy

Leadartis uses its novel and unique technological platforms to develop therapeutics in areas.

Trimerbodies competitive features

Trimerbodies have the potential to become next-generation drugs with enhanced potency

Intellectual property

Collaborations

The company has collaboration agreements with ...

OUR BLOG

Leadartis News

Talk With Our Experts

    Start typing and press Enter to search